PAP
CPRX

Persistent Asset Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Persistent Asset Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.3K Buy
+2,331
New +$68.8K 0.02% 359
2025
Q4 		– Sell
-11,441
Closed -$225K – 385
2025
Q3 		$225K Buy
+11,441
New +$235K 0.15% 126

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Persistent Asset Partners's CPRX Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 2,331 shares worth $73.3K. The stake represents 0.02% of the portfolio and ranks #359 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in CPRX as recently as Q3 2025.

Persistent Asset Partners first reported a position in CPRX in Q3 2025 and has held it in 2 quarters since. The position peaked at $225K in Q3 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Persistent Asset Partners held 2,331 shares of Catalyst Pharmaceutical worth $73.3K as of Q2 2026.
  • Catalyst Pharmaceutical was a new Persistent Asset Partners position in Q2 2026.
  • Catalyst Pharmaceutical made up 0.02% of Persistent Asset Partners's portfolio in Q2 2026, its #359 holding.
  • Persistent Asset Partners first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Catalyst Pharmaceutical position peaked at $225K in Q3 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.